• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.10% Nasdaq Up0.05%

    Cleveland BioLabs, Inc. (CBLI)

    -NasdaqCM
    2.10 Up 0.10(4.94%) 12:46PM EDT
    ProfileGet Profile for:
    Cleveland BioLabs, Inc.
    73 High Street
    Buffalo, NY 14203
    United States - Map
    Phone: 716-849-6810
    Fax: 716-849-6820
    Website: http://www.cbiolabs.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cleveland BioLabs, Inc.

    Key Executives 
     PayExercised
    Dr. Yakov N. Kogan Ph.D., MBA, 43
    Co-Founder, Chief Exec. Officer and Director
    287.00K0.00
    Dr. Langdon L. Miller M.D., 62
    Pres and Chief Medical Officer
    384.00K0.00
    Mr. C. Neil Lyons CPA, 59
    Chief Financial Officer, Exec. VP and Corp. Sec.
    296.00K0.00
    Dr. Andrei V. Gudkov Ph.D., D.Sci., 60
    Co-Founder, Chief Scientific Officer and Director
    N/AN/A
    Ms. Rachel Levine ,
    VP of Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders